{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["28(5)"],"submitter":["Lin D"],"funding":["Bristol-Myers Squibb"],"pubmed_abstract":["<h4>Background</h4>Nivolumab plus chemotherapy demonstrated clinically significant improvement in quality-adjusted survival versus chemotherapy alone as first-line treatment for advanced non-HER2-positive gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC) in the CheckMate 649 post-hoc quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis at 1-year minimum follow-up. We report Q-TWiST analysis results at 4-year minimum follow-up.<h4>Methods</h4>Q-TWiST methodology was applied post-hoc to CheckMate 649 study data from all randomized patients, patients with PD-L1 combined positive score (CPS) ≥ 1, and patients with PD-L1 CPS ≥ 5. Relative Q-TWiST gains ≥ 10% were predefined as clinically important and ≥ 15% as clearly clinically impor"],"journal":["Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association"],"pagination":["935-944"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12378121"],"repository":["biostudies-literature"],"pubmed_title":["Q-TWiST analysis of first-line nivolumab plus chemotherapy versus chemotherapy in patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma from CheckMate 649: 4-year follow-up results."],"pmcid":["PMC12378121"],"pubmed_authors":["Chirikov V","Sugarman R","Lin D","Garretson M","Davis C","Singh P","Chen C","Quan W"],"additional_accession":[]},"is_claimable":false,"name":"Q-TWiST analysis of first-line nivolumab plus chemotherapy versus chemotherapy in patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma from CheckMate 649: 4-year follow-up results.","description":"<h4>Background</h4>Nivolumab plus chemotherapy demonstrated clinically significant improvement in quality-adjusted survival versus chemotherapy alone as first-line treatment for advanced non-HER2-positive gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC) in the CheckMate 649 post-hoc quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis at 1-year minimum follow-up. We report Q-TWiST analysis results at 4-year minimum follow-up.<h4>Methods</h4>Q-TWiST methodology was applied post-hoc to CheckMate 649 study data from all randomized patients, patients with PD-L1 combined positive score (CPS) ≥ 1, and patients with PD-L1 CPS ≥ 5. Relative Q-TWiST gains ≥ 10% were predefined as clinically important and ≥ 15% as clearly clinically impor","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-05-10T04:24:06.238Z","creation":"2026-04-08T01:28:00.201Z"},"accession":"S-EPMC12378121","cross_references":{"pubmed":["40632415"],"doi":["10.1007/s10120-025-01634-6"]}}